What to Expect on Tesamorelin: Week by Week Timeline

The first two weeks are focused on establishing consistent growth hormone release patterns. Some users report subtle improvements in sleep quality and morning energy, similar to other GH secretagogues. Measurable body composition changes are not expected during this early phase.

The body is adjusting to sustained growth hormone optimization during this window. IGF-1 levels typically begin to rise and can be confirmed through lab work. Some patients describe a gradual improvement in overall energy and exercise recovery, though the visceral fat changes are still building beneath the surface.

This is the window where imaging studies or precise body composition scans may first reveal measurable reductions in visceral fat. Waist circumference changes are sometimes noticeable, though superficial fat deposits may not change as visibly. Many people report improved metabolic lab values around this time, including fasting glucose and triglycerides.

The four- to six-month mark is commonly associated with the most clinically meaningful reductions in visceral adipose tissue. Abdominal imaging comparisons at this stage often show substantial decreases that correlate with improved cardiometabolic risk markers. Many patients describe feeling that their body shape has changed in a way that differs from typical diet-induced fat loss.

Long-term Tesamorelin use is commonly structured with regular monitoring of IGF-1 levels and visceral fat imaging. Some individuals achieve their goals and transition to a maintenance approach, while others continue the full protocol. The metabolic benefits, including improved insulin sensitivity and lipid profiles, have been associated with sustained use over twelve months.